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OBJECTIVES: The long-term beneﬁts on life expectancy
of more effective antihypertensive strategies to lower
blood pressure are not well described, particularly for
certain groups with different cardiovascular (CV) risk
factor proﬁles. We projected the life expectancy beneﬁts
of anti-hypertensive treatment strategies using a unique
primary/secondary prevention Markov Model derived
from a large epidemiologic database. 
METHODS: Longitudinal data from 57,279 middle-aged
and older male and female health professionals were
pooled to develop a primary and secondary CV event
Markov model estimating the long-term beneﬁts of anti-
hypertensive treatment based on both systolic and dias-
tolic blood pressure reduction. Seven patient states were
deﬁned: no CV event history, stroke, myocardial infarc-
tion, revascularization, non-CV death, CV death, and
history of CV event. Risk functions were developed from
gender-speciﬁc multivariate Cox proportional hazards
models for primary events, and age-adjusted models for
secondary events. The area between survival curves of 
different interventions was calculated to estimate the
incremental gains in life expectancy for the superior anti-
hypertensive treatment intervention.
RESULTS: We assumed a pre-treatment blood pressure
of 160mmHg systolic/95mmHg diastolic. We further
assumed that Strategy A yields a lowering of 20/13mm
Hg and Strategy B yields a reduction of 13/8mmHg. Post
treatment blood pressures at the start of the simulation
were thus 140/82mmHg for Strategy A and 147/87mm
Hg for Strategy B. Assuming an age of 35 years at base-
line and cycling the model for 65 years, a life expectancy
gain of 0.7 years is achieved for Strategy A versus 
Strategy B. In a diabetic population, there was a life
expectancy gain of 0.79 years for Strategy A versus 
Strategy B.
CONCLUSIONS: Substantial gains in life expectancy 
due to reduction in both primary and secondary CV
events can be achieved by superior strategies of blood
pressure lowering.
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OBJECTIVE: To estimate the average cost of anti-
coagulation clinic services from a provider perspective. 
METHODS: Using a retrospective cohort approach, a
random sample of 600 patients was selected from 3 geo-
graphically diverse managed care sites (N = 200 per site)
with anticoagulation clinics and followed for up to one
year. Care was provided under a traditional nurse or
pharmacist managed clinic model with most encounters
involving telephone contacts. Study patients included
adults aged 18+ years with a diagnosis of nonvalvular
atrial ﬁbrillation who received warfarin for at least 30
days. Patient contacts were evaluated based on complex-
ity (education, warfarin dose adjusted, warfarin dose not
adjusted) and the total cost of anticoagulation clinic care
was calculated for staff time, laboratory tests, and over-
head. Unit costs were estimated based on national data.
Labor costs were measured by observing the actual time
spent by clinic staff on individual patient encounters using
a prospective time study (“activity-based” approach), and
through a survey of budgeted labor hours (“budgeted-
cost” approach).
RESULTS: The average age of patients was 72 years 
and 56% were female. Approximately 85% were white.
About 75% of patients completed one year of clinic
follow-up (mean duration: 10.5 months). Patients aver-
aged 18 clinic contacts. The cost of staff time for war-
farin monitoring during follow-up was estimated to be
$91 under the activity-based approach and $176 using
the budgeted-cost approach. These costs increased to
$244 and $330 for the activity-based and budgeted-cost
approaches, respectively, once laboratory tests and over-
head were included. Average costs for patients who were
followed for a full year were $268 and $362, respectively.
While anticoagulation control was relatively similar
across sites (60% to 65% time in INR range), there was
more marked variation in costs.
CONCLUSIONS: This study provides a detailed, multi-
site assessment of the costs of warfarin monitoring using
multiple costing methodologies.
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Atrial ﬁbrillation (AF), the most common persistent
arrhythmia, increases the risk of stroke manifolds. This
risk is further enhanced in the presence of underlying 
cardiovascular diseases (CVD). Yet, the health care costs
and utilization associated with this condition have not
been well studied.
OBJECTIVE: To compare the resource utilization and
costs among patients with and without AF in an
employer-based privately insured population with under-
lying CVD. 
METHODS: Retrospective claims data from a large
group of self-insured employers were used. Patients con-
tinuously enrolled from January 1, 1996 to December 31,
